Is the sirolimus drug eluting stent better than paclitaxel coated stent in "real life" environment?
Détails
ID Serval
serval:BIB_7C064190E600
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Is the sirolimus drug eluting stent better than paclitaxel coated stent in "real life" environment?
Titre de la conférence
53rd Annual Scientific Session of the American College of Cardiology (ACC)
Adresse
New Orleans, Louisiana, United-States, March 7-10, 2004
ISBN
0735-1097
ISSN-L
0735-1097
Statut éditorial
Publié
Date de publication
2004
Volume
43
Série
Journal of the American College of Cardiology
Pages
A86
Langue
anglais
Résumé
Background: Active stents seems to improve the outcome after percutaneous intervention
(PCI) in reducing MACE at 9 months. However no prospective data comparing various
devices are available.
Method: Since March 2003, all patients suitable for stent implantation were randomized
to receive either a sirolimus eluting stent (SES) or a paclitaxel active stent (PAS). Standard
procedures were performed. Aspirin and clopidogrel were initiated for at least one
year. Clinical outcome (MACE incidence at 9 months) is the primary end-point. Control
angiography was performed only when clinically driven.
Results: A total of 102 pts were included (mean age 66±11), (24 female), received a 54
SES and 48 a PAS. Demographic data were comparable with a proportion of 8 pts with
unstable angina. Diabetes was present in 7 pts the SES group and in 6 pts in the PAS
group. Baseline data and follow-up at 3 months are presented in the table below:The incidence
of MACE did not differ after a mean follow-up of 3 ±4 months between the 2
groups. Particularly no pt died in either group. MI did not occur either. Only sub-acute
thrombosis was documented in 2 pts in the PAS group. TLR and TVR were required in 0
pts in the SES group versus 2 pts in the PAS group.
Conclusion: There was no significant difference in the incidence of MACE between sirolimus
and paclitaxel group during this short follow-up. Nine-month follow-up will be available
at time of presentation.
(PCI) in reducing MACE at 9 months. However no prospective data comparing various
devices are available.
Method: Since March 2003, all patients suitable for stent implantation were randomized
to receive either a sirolimus eluting stent (SES) or a paclitaxel active stent (PAS). Standard
procedures were performed. Aspirin and clopidogrel were initiated for at least one
year. Clinical outcome (MACE incidence at 9 months) is the primary end-point. Control
angiography was performed only when clinically driven.
Results: A total of 102 pts were included (mean age 66±11), (24 female), received a 54
SES and 48 a PAS. Demographic data were comparable with a proportion of 8 pts with
unstable angina. Diabetes was present in 7 pts the SES group and in 6 pts in the PAS
group. Baseline data and follow-up at 3 months are presented in the table below:The incidence
of MACE did not differ after a mean follow-up of 3 ±4 months between the 2
groups. Particularly no pt died in either group. MI did not occur either. Only sub-acute
thrombosis was documented in 2 pts in the PAS group. TLR and TVR were required in 0
pts in the SES group versus 2 pts in the PAS group.
Conclusion: There was no significant difference in the incidence of MACE between sirolimus
and paclitaxel group during this short follow-up. Nine-month follow-up will be available
at time of presentation.
Création de la notice
28/01/2008 11:11
Dernière modification de la notice
20/08/2019 15:37
Données d'usage
